IBRX - Company ID 0001326110
The table below shows ImmunityBio, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $44.21M | $32.06M | $26.43M | $16.52M | $6.11M | $1.05M |
| Cost of revenue | $238.00K | $177.00K | $136.00K | $58.00K | $0.00 | $0.00 |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | $50.44M | $51.13M |
ImmunityBio, Inc. reported annual revenue of $113.29M for fiscal year 2025. That is up 668.3% from $14.74M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $44.00K (FY 2016) to $113.29M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| - |
| - |
| - |
| - |
| $35.92M |
| $49.25M |
| Operating income | -$69.79M | -$55.63M | -$71.28M | -$64.43M | -$80.25M | -$99.33M |
| Income tax | $9.00K | -$35.00K | $269.00K | -$234.00K | $0.00 | $0.00 |
| Net income | -$632.78M | -$67.25M | -$92.56M | -$129.65M | -$85.73M | -$134.56M |
| EPS (diluted) | -$0.62 | -$0.07 | -$0.10 | -$0.15 | -$0.14 | -$0.20 |